High Times for Painful Blues: The Endocannabinoid System in Pain-Depression Comorbidity
Open accessThe DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Abstract
Depression and pain are two of the most debilitating disorders worldwide and have an estimated cooccurrence of up to 80%. Comorbidity of these disorders is more difficult to treat, associated with significant disability and impaired health-related quality of life than either condition alone, resulting in enormous social and economic cost. Several neural substrates have been identified as potential mediators in the association between depression and pain, including neuroanatomical reorganization, monoamine and neurotrophin depletion, dysregulation of the hypothalamo-pituitary-adrenal axis, and neuroinflammation. However, the past decade has seen mounting evidence supporting a role for the endogenous cannabinoid (endocannabinoid) system in affective and nociceptive processing, and thus, alterations in this system may play a key role in reciprocal interactions between depression and pain. This review will provide an overview of the preclinical evidence supporting an interaction between depression and pain and the evidence supporting a role for the endocannabinoid system in this interaction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Millan, M. J. (2002) · Progress in Neurobiology · doi:10.1016/s0301-0082(02)00009-6 · Cited by 3,035
Determination and characterization of a cannabinoid receptor in rat brain
Devane, W. A., Dysarz, F. A., Johnson, M. R., Melvin, L. S., & Howlett, A. C. (1988) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09876-1 · Cited by 2,443 · cited 1×
“This endocannabinoid system consists of the cannabinoid receptors (CB1 and CB2) (Devane et al., 1988; Matsuda et al., 1990; Munro et al., 1993), their naturally occurring endogenous ligands (the best characterized of which are N-arachidonoylethanolamine, or anandamide [AEA]) (Devane et al.”
BackgroundCannabinoid receptor localization in brain.
Herkenham, M., Lynn, A. B., Little, M. D., Johnson, M. R., Melvin, L. S., de Costa, B. R., & Rice, K. C. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.5.1932 · Cited by 2,321
2-Arachidonoylgylcerol: A Possible Endogenous Cannabinoid Receptor Ligand in Brain
Sugiura, T., Kondo, S., Sukagawa, A., Nakane, S., Shinoda, A., Itoh, K., Yamashita, A., & Waku, K. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.2437 · Cited by 2,196
Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides
Cravatt, B. F., Giang, D. K., Mayfield, S. P., Boger, D. L., Lerner, R. A., & Gilula, N. B. (1996) · Nature · doi:10.1038/384083a0 · Cited by 2,125 · cited 1×
“, 1996), while fatty acid amide hydrolase (FAAH) is the primary enzyme responsible for the metabolism of this endocannabinoid (Cravatt et al., 1996).”
BackgroundImmunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system
Tsou, K., Brown, S., Sañudo-Peña, M. C., Mackie, K., & Walker, J. M. (1998) · Neuroscience · doi:10.1016/s0306-4522(97)00436-3 · Cited by 1,586
The orphan receptor GPR55 is a novel cannabinoid receptor
Ryberg, E., Larsson, N., Sjögren, S., Hjorth, S., Hermansson, N., Leonova, J., Elebring, T., Nilsson, K., Drmota, T., & Greasley, P. J. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707460 · Cited by 1,568
Identification and Functional Characterization of Brainstem Cannabinoid CB2Receptors
Van Sickle, M. D., Duncan, M., Kingsley, P. J., Mouihate, A., Urbani, P., Mackie, K., Stella, N., Makriyannis, A., Piomelli, D., Davison, J. S., et al. (2005) · Science · doi:10.1126/science.1115740 · Cited by 1,470
A Comprehensive Profile of Brain Enzymes that Hydrolyze the Endocannabinoid 2-Arachidonoylglycerol
Blankman, J. L., Simon, G. M., & Cravatt, B. F. (2007) · Chemistry & Biology · doi:10.1016/j.chembiol.2007.11.006 · Cited by 1,177 · cited 3×
“(Blankman et al., 2007), although other enzymes including cyclooxygenase-2 (Yu et al., 1997; Kozak et al., 2000), lipoxygenase (van der Stelt et al., 2002), ABDH6 (serine hydrolase α/β-hydrolase domain), and ABDH12 (Blankman et al., 2007), have also been shown to play a role.”
BackgroundInfluentialCannabinoid CB2 receptors: immunohistochemical localization in rat brain
Gong, J.-P., Onaivi, E. S., Ishiguro, H., Liu, Q.-R., Tagliaferro, P. A., Brusco, A., & Uhl, G. R. (2006) · Brain Research · doi:10.1016/j.brainres.2005.11.035 · Cited by 820
Inflammation-associated depression: From serotonin to kynurenine
Dantzer, R., O’Connor, J. C., Lawson, M. A., & Kelley, K. W. (2011) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2010.09.012 · Cited by 726
Maes, M., Leonard, B. E., Myint, A. M., Kubera, M., & Verkerk, R. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.12.017 · Cited by 700
Katona, I., Rancz, E. A., Acsády, L., Ledent, C., Mackie, K., Hájos, N., & Freund, T. F. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-23-09506.2001 · Cited by 668
Cannabinoid Receptors: Where They are and What They do
Mackie, K. (2008) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2008.01671.x · Cited by 638
Opioid receptors: Distinct roles in mood disorders
Lutz, P.-E., & Kieffer, B. L. (2013) · Trends in Neurosciences · doi:10.1016/j.tins.2012.11.002 · Cited by 542
Patel, S., Roelke, C. T., Rademacher, D. J., Cullinan, W. E., & Hillard, C. J. (2004) · Endocrinology · doi:10.1210/en.2004-0638 · Cited by 475
Neuroinflammation and comorbidity of pain and depression
Walker, A. K., Kavelaars, A., Heijnen, C. J., & Dantzer, R. (2014) · Pharmacological Reviews · doi:10.1124/pr.113.008144 · Cited by 460 · cited 3×
“The innate inflammatory cascade has been shown to increase glutamate neurotransmission, central sensitization, and excitotoxicity, reduce BDNF and neurogenesis, and activate neurodegenerative cascades, events observed in both depression and pain conditions (for review, see Dantzer et al., 2011; Maes et al., 2011; Song…”
BackgroundZhang, J., Hoffert, C., Vu, H. K., Groblewski, T., Ahmad, S., & O'Donnell, D. (2003) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2003.02704.x · Cited by 419
An analgesia circuit activated by cannabinoids
Meng, I. D., Manning, B. H., Martin, W. J., & Fields, H. L. (1998) · Nature · doi:10.1038/26481 · Cited by 411
Tuglu, C., Kara, S. H., Caliyurt, O., Vardar, E., & Abay, E. (2003) · Psychopharmacology · doi:10.1007/s00213-003-1566-z · Cited by 391
Kozak, K. R., Rowlinson, S. W., & Marnett, L. J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m007088200 · Cited by 390 · cited 1×
“, 2007), although other enzymes including cyclooxygenase-2 (Yu et al., 1997; Kozak et al., 2000), lipoxygenase (van der Stelt et al.”
BackgroundNabilone for the treatment of pain in fibromyalgia.
Skrabek, R. Q., Galimova, L., Ethans, K., & Perry, D. (2008) · The Journal of Pain · doi:10.1016/j.jpain.2007.09.002 · Cited by 384 · cited 1×
“While no study to date has specifically evaluated the effects of cannabinoids on depression-pain comorbidity, several have examined effects on mood and quality of life in patients receiving cannabinoid-based pharmaceuticals for analgesic purposes (Maida et al., 2008; Skrabek et al., 2008; Weber et al., 2009; Cameron e…”
BackgroundHuggins, J. P., Smart, T. S., Langman, S., Taylor, L., & Young, T. (2012) · Pain · doi:10.1016/j.pain.2012.04.020 · Cited by 375
HPA axis and aging in depression: Systematic review and meta-analysis
Belvederi Murri, M., Pariante, C., Mondelli, V., Masotti, M., Atti, A. R., Mellacqua, Z., Antonioli, M., Ghio, L., Menchetti, M., Zanetidou, S., et al. (2014) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2013.12.004 · Cited by 367
Hill, M. N., Patel, S., Carrier, E. J., Rademacher, D. J., Ormerod, B. K., Hillard, C. J., & Gorzalka, B. B. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300601 · Cited by 363
Cannabinoids Enhance Subsecond Dopamine Release in the Nucleus Accumbens of Awake Rats
Cheer, J. F., Wassum, K. M., Heien, M. L. A. V., Phillips, P. E. M., & Wightman, R. M. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.0529-04.2004 · Cited by 343
Zhang, H.-Y., Gao, M., Liu, Q.-R., Bi, G.-H., Li, X., Yang, H.-J., Gardner, E. L., Wu, J., & Xi, Z.-X. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1413210111 · Cited by 334
Hill, M. N., Miller, G. E., Carrier, E. J., Gorzalka, B. B., & Hillard, C. J. (2009) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2009.03.013 · Cited by 328
Bambico, F. R., Katz, N., Debonnel, G., & Gobbi, G. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.1636-07.2007 · Cited by 325
Jennings, E. M., Okine, B. N., Roche, M., & Finn, D. P. (2014) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2014.06.003 · Cited by 318
Self-citationBay-Richter, C., Linderholm, K. R., Lim, C. K., Samuelsson, M., Träskman-Bendz, L., Guillemin, G. J., Erhardt, S., & Brundin, L. (2015) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2014.07.012 · Cited by 304 · cited 1×
“Furthermore, increases in serum and cerebrospinal fluid levels of proinflammatory cytokines have been widely reported in both depression (Tuglu et al., 2003; Knuth et al., 2014; Bay-Richter et al., 2015) and pain conditions (Koch et al.”
BackgroundRichardson, D., Pearson, R. G., Kurian, N., Latif, M. L., Garle, M. J., Barrett, D. A., Kendall, D. A., Scammell, B. E., Reeve, A. J., & Chapman, V. (2008) · Arthritis Research & Therapy · doi:10.1186/ar2401 · Cited by 303
Chronic pain induces anxiety with concomitant changes in opioidergic function in the amygdala
Narita, M., Kaneko, C., Miyoshi, K., Nagumo, Y., Kuzumaki, N., Nakajima, M., Nanjo, K., Matsuzawa, K., Yamazaki, M., & Suzuki, T. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300858 · Cited by 289
Pain and Depression: An Integrative Review of Neurobiological and Psychological Factors
Goesling, J., Clauw, D. J., & Hassett, A. L. (2013) · Current Psychiatry Reports · doi:10.1007/s11920-013-0421-0 · Cited by 285
Hill, M. N., Carrier, E. J., McLaughlin, R. J., Morrish, A. C., Meier, S. E., Hillard, C. J., & Gorzalka, B. B. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05567.x · Cited by 246
Corticotropin-releasing hormone drives anandamide hydrolysis in the amygdala to promote anxiety
Gray, J. M., Vecchiarelli, H. A., Morena, M., Lee, T. T. Y., Hermanson, D. J., Kim, A. B., McLaughlin, R. J., Hassan, K. I., Kühne, C., Wotjak, C. T., et al. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.2737-14.2015 · Cited by 246 · cited 1×
“Furthermore, recent evidence has shown that CRF1 activation in the amygdala induces FAAH and reduces AEA levels, an effect associated with anxiety-related behavior (Gray et al., 2015).”
BackgroundDomenici, M. R., Azad, S. C., Marsicano, G., Schierloh, A., Wotjak, C. T., Dodt, H.-U., Zieglgänsberger, W., Lutz, B., & Rammes, G. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.0372-06.2006 · Cited by 224
Norman, G. J., Karelina, K., Zhang, N., Walton, J. C., Morris, J. S., & DeVries, A. C. (2010) · Molecular Psychiatry · doi:10.1038/mp.2009.91 · Cited by 209
Cannabis use in HIV for pain and other medical symptoms
Woolridge, E., Barton, S., Samuel, J., Osorio, J., Dougherty, A., & Holdcroft, A. (2005) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2004.07.011 · Cited by 208
Mitrirattanakul, S., Ramakul, N., Guerrero, A. V., Matsuka, Y., Ono, T., Iwase, H., Mackie, K., Faull, K. F., & Spigelman, I. (2006) · Pain · doi:10.1016/j.pain.2006.06.016 · Cited by 207
Cota, D., Steiner, M.-A., Marsicano, G., Cervino, C., Herman, J. P., Grübler, Y., Stalla, J., Pasquali, R., Lutz, B., Stalla, G. K., et al. (2007) · Endocrinology · doi:10.1210/en.2005-1649 · Cited by 205
Capuron, L., Ravaud, A., Gualde, N., Bosmans, E., Dantzer, R., Maes, M., & Neveu, P. J. (2001) · Psychoneuroendocrinology · doi:10.1016/s0306-4530(01)00030-0 · Cited by 201
Lim, G., Sung, B., Ji, R.-R., & Mao, J. (2003) · Pain · doi:10.1016/s0304-3959(03)00242-2 · Cited by 195 · cited 2×
“Despite numerous reports of altered endocannabinoid signaling in various animal models of pain (Lim et al., 2003; Zhang et al., 2003; Walczak et al., 2005; Mitrirattanakul et al., 2006) and mood-related behavior (Vinod et al., 2012; Marco et al., 2014; Navarria et al., 2014), there is limited…”
BackgroundCapuron, L., & Ravaud, A. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904293401716 · Cited by 169
Antinociceptive Synergy between Δ9-Tetrahydrocannabinol and Opioids after Oral Administration
Cichewicz, D. L., & McCarthy, E. A. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.045575 · Cited by 154 · cited 2×
“Coadministration of opioids and cannabinoids results in synergistic and bidirectional antinociceptive effects in several animal models (Cichewicz et al., 1999; Cichewicz and McCarthy, 2003; Tham et al., 2005; Roberts et al., 2006; Smith et al., 2007; Wilson et al., 2008; Wilson-Poe et al., 2013).”
BackgroundThe risk of suicide mortality in chronic pain patients
Hassett, A. L., Aquino, J. K., & Ilgen, M. A. (2014) · Current Pain and Headache Reports · doi:10.1007/s11916-014-0436-1 · Cited by 140
Hu, B., Doods, H., Treede, R.-D., & Ceci, A. (2009) · Pain · doi:10.1016/j.pain.2009.02.018 · Cited by 138
Knaster, P., Karlsson, H., Estlander, A.-M., & Kalso, E. (2012) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2011.09.004 · Cited by 136
Barna, I., Zelena, D., Arszovszki, A. C., & Ledent, C. (2004) · Life Sciences · doi:10.1016/j.lfs.2004.06.006 · Cited by 136
Walczak, J.-S., Pichette, V., Leblond, F., Desbiens, K., & Beaulieu, P. (2005) · Neuroscience · doi:10.1016/j.neuroscience.2005.02.010 · Cited by 133
Depression in chronic pain patients: Prevalence and measurement
Poole, H., White, S., Blake, C., Murphy, P., & Bramwell, R. (2009) · Pain Practice · doi:10.1111/j.1533-2500.2009.00274.x · Cited by 129
Synergistic affective analgesic interaction between delta-9-tetrahydrocannabinol and morphine
Roberts, J. D., Gennings, C., & Shih, M. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2005.11.036 · Cited by 103
Burston, J. J., Sagar, D. R., Shao, P., Bai, M., King, E., Brailsford, L., Turner, J. M., Hathway, G. J., Bennett, A. J., Walsh, D. A., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080440 · Cited by 103 · cited 1×
“In addition, several studies have demonstrated that the analgesic effects of cannabinoids in chronic inflammatory and neuropathic pain are at least partially mediated by modulation of inflammatory responses (Burgos et al., 2012; Wilkerson et al., 2012; Burston et al., 2013; Lu et al., 2015).”
BackgroundTham, S. M., Angus, J. A., Tudor, E. M., & Wright, C. E. (2005) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706045 · Cited by 98
Zhang, Z., Wang, W., Zhong, P., Liu, S. J., Long, J. Z., Zhao, L., Gao, H., Cravatt, B. F., & Liu, Q. (2015) · Hippocampus · doi:10.1002/hipo.22344 · Cited by 89 · cited 7×
“Pretreatment with the FAAH inhibitor, URB597, or MAGL inhibitor, JZL184, which enhanced endogenous levels of AEA and 2-AG, respectively, significantly attenuated CUS-induced anxiety-related behavior in the lightdark box and concurrent thermal hyperalgesia (Lomazzo et al., 2015).”
BackgroundInfluentialPalazzo, E., De Novellis, V., Petrosino, S., Marabese, I., Vita, D., Giordano, C., Di Marzo, V., Mangoni, G. S., Rossi, F., & Maione, S. (2006) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.05086.x · Cited by 86
Rossi, S., De Chiara, V., Musella, A., Sacchetti, L., Cantarella, C., Castelli, M., Cavasinni, F., Motta, C., Studer, V., Bernardi, G., et al. (2010) · Molecular Pharmacology · doi:10.1124/mol.110.064196 · Cited by 82
Smith, P. A., Selley, D. E., Sim-Selley, L. J., & Welch, S. P. (2007) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.06.001 · Cited by 81
Wilson-Poe, A. R., Morgan, M. M., Aicher, S. A., & Hegarty, D. M. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2012.03.038 · Cited by 79 · cited 1×
“CB1 and μ-opioid receptors are highly colocalized on neurons in areas of the brain associated with emotional and pain processing such as the caudate putamen, periaqueductal gray, and spinal cord (Rodriguez et al., 2001; Salio et al., 2001; Wilson-Poe et al., 2012).”
BackgroundFinn, D. P., Beckett, S. R. G., Richardson, D., Kendall, D. A., Marsden, C. A., & Chapman, V. (2004) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2004.03509.x · Cited by 66
Self-citationMcLaughlin, R. J., Hill, M. N., Dang, S. S., Wainwright, S. R., Galea, L. A. M., Hillard, C. J., & Gorzalka, B. B. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.09.053 · Cited by 65 · cited 1×
“, 2007), a decrease in CB1 receptor density in the hypothalamus and striatum and increased CB1 receptor density in the prefrontal cortex (Hill et al., 2008a; McLaughlin et al., 2013), a reduction in 2-AG–mediated retrograde synaptic transmission in the hippocampus (Zhong et al.”
BackgroundWilson, A. R., Maher, L., & Morgan, M. M. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.07.038 · Cited by 52
Miller, L. L., Picker, M. J., Umberger, M. D., Schmidt, K. T., & Dykstra, L. A. (2012) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.191478 · Cited by 44 · cited 1×
“However, the FAAH inhibitor URB597 exhibits a dose-related and CB1 receptor-mediated decrease in acid-stimulated stretching and suppression of feeding (Miller et al., 2012; Kwilasz et al., 2014).”
BackgroundYasuda, S., Yoshida, M., Yamagata, H., Iwanaga, Y., Suenaga, H., Ishikawa, K., Nakano, M., Okuyama, S., Furukawa, Y., Furukawa, S., et al. (2014) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-014-0097-y · Cited by 34 · cited 5×
“In addition, direct administration of a BDNF inducer (4-MC) into the brain attenuated thermal hyperalgesia and depressivelike behavior following nerve injury (Fukuhara et al., 2012; Ishikawa et al., 2014).”
BackgroundInfluential
Cited by
Pain and Depression: A Systematic Review
IsHak, W. W., Wen, R. Y., Naghdechi, L., Vanle, B., Dang, J., Knosp, M., Dascal, J., Marcia, L., Gohar, Y., Eskander, L., et al. (2018) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000198 · Cited by 498
Burke, N. N., Finn, D. P., McGuire, B. E., & Roche, M. (2017) · Journal of Neuroscience Research · doi:10.1002/jnr.23802 · Cited by 268
Self-citationThe cannabinoid system and pain
Woodhams, S. G., Chapman, V., Finn, D. P., Hohmann, A. G., & Neugebauer, V. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.06.015 · Cited by 267
Self-citationCannabinoids, the endocannabinoid system, and pain: a review of preclinical studies
Finn, D. P., Haroutounian, S., Hohmann, A. G., Krane, E., Soliman, N., & Rice, A. S. C. (2021) · Pain · doi:10.1097/j.pain.0000000000002268 · Cited by 254
Self-citationNon‐Motor Symptoms in Parkinson's Disease are Reduced by Nabilone
Peball, M., Krismer, F., Knaus, H., Djamshidian, A., Werkmann, M., Carbone, F., Ellmerer, P., Heim, B., Marini, K., Valent, D., et al. (2020) · Annals of Neurology · doi:10.1002/ana.25864 · Cited by 123
Metadata
- Authors
- Fitzgibbon, M., Finn, D. P., & Roche, M.
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-09-05
- Volume
- 19
- Issue
- 3
- Pages
- pyv095
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- OpenAlex
- W2147193741
- Cited by
- 57
- References
- 64
- FWCI
- 2.75
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.